↓ Skip to main content

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and…

Overview of attention for article published in Frontiers in oncology, March 2024
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Published in
Frontiers in oncology, March 2024
DOI 10.3389/fonc.2024.1367450
Pubmed ID
Authors

Christopher Hackenbruch, Jens Bauer, Jonas S. Heitmann, Yacine Maringer, Annika Nelde, Monika Denk, Lisa Zieschang, Christine Kammer, Birgit Federmann, Susanne Jung, Peter Martus, Nisar P. Malek, Konstantin Nikolaou, Helmut R. Salih, Michael Bitzer, Juliane S. Walz

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 1 100%
Readers by discipline Count As %
Engineering 1 100%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2024.
All research outputs
#20,621,745
of 26,202,139 outputs
Outputs from Frontiers in oncology
#9,648
of 22,934 outputs
Outputs of similar age
#223,582
of 345,540 outputs
Outputs of similar age from Frontiers in oncology
#185
of 564 outputs
Altmetric has tracked 26,202,139 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,934 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,540 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 564 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.